Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by ronrydellon Jan 18, 2023 10:20am
151 Views
Post# 35230442

Litigation option

Litigation optionI find it hard to believe that litigation or an injunction  of some sort would happen in this lopsided deal that has such an adverse effect for the Bioasis shareholders. When a firm hires an investment banker to hopefully enhance their current situation they are hired to help the firm that hired them as opposed to using there exclusive mandate to enrich themselves in such an egregious way!

There are blocks of shareholders currently teaming up to study alternatives (the 460 page doc that describes the circular that Bioasis put out) and is being studied currently by well healed current shareholders who will decide how they vote. I can't predict how it will turn out but I don't think the the people controlling this deal will not want to walk away as opposed to revising and sweetening the deal for the much maligned Bioasis shareholders if an affirmative vote bringing the deal to fruition is perceived to not happen in February, 2023

all in my humble opinion.
<< Previous
Bullboard Posts
Next >>